BioMarin Pharmaceuticals BMRN Consideration paid, net of cash acquired
Discontinued — last reported Q4 '25
Consideration paid, net of cash acquired at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept bmrn:PaymentsForAssetAcquisitionsNetOfCashAcquired.
The official record: BioMarin Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's consideration paid, net of cash acquired.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's consideration paid, net of cash acquired?
- BioMarin Pharmaceuticals (BMRN) reported consideration paid, net of cash acquired of $71.3M in Q4 2025.
- What does consideration paid, net of cash acquired mean?
- Net cash spent on buying other companies or business assets.
- How do you interpret consideration paid, net of cash acquired?
- Significant outflows indicate aggressive inorganic growth, while zero or low values suggest a focus on organic development.
- How does consideration paid, net of cash acquired compare across companies?
- Varies significantly based on the company's M&A cycle; common in the pharmaceutical sector for acquiring late-stage clinical assets.